Gilead Sciences acquired MiroBio Ltd. for $414 million cash, a transaction announced in September 2022.
Acquired the privately-held U.K. biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. Accounted for as an asset acquisition.
Acquired the privately-held U.K. biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. Accounted for as an asset acquisition.
Advisory firms were not disclosed for this transaction.